News stories about Magellan Health (NASDAQ:MGLN) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Magellan Health earned a news sentiment score of 0.06 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.1611459188702 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Several analysts have recently issued reports on the company. Zacks Investment Research cut Magellan Health from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. ValuEngine upgraded Magellan Health from a “hold” rating to a “buy” rating in a research note on Sunday, December 31st. KeyCorp reiterated a “buy” rating and issued a $89.00 price objective on shares of Magellan Health in a research note on Friday, September 22nd. Raymond James Financial reiterated a “hold” rating on shares of Magellan Health in a research note on Saturday, December 2nd. Finally, BidaskClub cut Magellan Health from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 19th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $96.00.

Shares of Magellan Health (NASDAQ:MGLN) opened at $98.25 on Friday. The stock has a market capitalization of $2,376.58, a price-to-earnings ratio of 25.92, a PEG ratio of 1.16 and a beta of 0.53. The company has a quick ratio of 2.21, a current ratio of 2.28 and a debt-to-equity ratio of 0.62. Magellan Health has a 52 week low of $64.05 and a 52 week high of $99.80.

Magellan Health (NASDAQ:MGLN) last announced its quarterly earnings data on Wednesday, November 1st. The company reported $1.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.24. The business had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Magellan Health had a return on equity of 9.20% and a net margin of 1.68%. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period last year, the firm earned $1.39 earnings per share. analysts anticipate that Magellan Health will post 5.19 EPS for the current year.

In other Magellan Health news, CEO Mostafa Kamal sold 1,154 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $92.00, for a total value of $106,168.00. Following the sale, the chief executive officer now directly owns 1,154 shares in the company, valued at $106,168. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Clapper Caskie Lewis sold 59,313 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $93.99, for a total value of $5,574,828.87. Following the completion of the sale, the insider now owns 48,474 shares in the company, valued at $4,556,071.26. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 111,101 shares of company stock worth $10,412,588. 3.60% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Magellan Health (MGLN) Stock Price” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at

About Magellan Health

Magellan Health, Inc is engaged in the healthcare management business. The Company’s segments include Healthcare, Pharmacy Management and Corporate. It is focused on managing special populations, complete pharmacy benefits and other specialty areas of healthcare. Its Healthcare includes its management of behavioral healthcare services and employee assistance program (EAP) services, management of other specialty areas, including diagnostic imaging and musculoskeletal management, and the integrated management of physical, behavioral and pharmaceutical healthcare for special populations, delivered through Magellan Complete Care (MCC).

Insider Buying and Selling by Quarter for Magellan Health (NASDAQ:MGLN)

Receive News & Ratings for Magellan Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magellan Health and related companies with Analyst Ratings Network's FREE daily email newsletter.